Biolex Therapeutics
closedBiolex Therapeutics developed therapeutic proteins and monoclonal antibodies that had been optimized to enhance their efficacy and potency.
Launch date
Employees
Market cap
-
Enterprise valuation
$80—120m (Dealroom.co estimates Oct 2010.)
Pittsboro North Carolina (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$24.4m | Late VC | ||
| N/A | $8.0m | Early VC | |
$36.0m | Series B | ||
$30.0m | Series C | ||
| N/A | $60.0m | Series D | |
| N/A | $10.0m | Debt | |
| N/A | $20.0m | Series D | |
| N/A | $5.9m | Debt | |
| N/A | $2.4m | Debt | |
| Total Funding | $178m | ||
Related Content
Recent News about Biolex Therapeutics
EditInvestments by Biolex Therapeutics
Edit
ACQUISITION by Biolex Therapeutics May 2004
ACQUISITION by Biolex Therapeutics Jul 2005